Abbott Stock Surges 6%: How Diagnostics Growth Drives 2026 Profit Guidance Raise and Investor Sentiment

Abbott Laboratories (ABT) shares surged more than 6% in early trading Friday, following a second-quarter earnings beat that prompted management to raise its full-year 2026 profit guidance. The rally is the strongest single-day gain for the stock in over two years.

The diagnostics segment is the primary driver. Revenue from diagnostics rose 11% year-over-year to $4.2 billion, outpacing all other business lines. This growth was fueled by demand for rapid testing platforms and infectious disease assays.

The Catalyst: Abbott Q2 2026 Earnings Beat and Full-Year Profit Guidance Raise

Abbott reported adjusted earnings per share of $1.45 for the quarter ended June 30, surpassing the consensus estimate of $1.38. Revenue reached $11.8 billion, up 7.5% from the same period last year.

The company now expects full-year 2026 adjusted EPS in the range of $5.50 to $5.60, up from its prior forecast of $5.30 to $5.45. This marks the first guidance increase in three quarters.

Diagnostics Growth: The Core Engine Behind Abbott’s Revenue Momentum

Diagnostics sales growth was broad-based. Within the segment, point-of-care testing revenue jumped 15%, driven by new product launches. Core laboratory diagnostics grew 9%, while rapid diagnostics saw a 12% uptick.

This performance contrasts sharply with Abbott’s other segments. Medical devices grew 4%, nutrition rose 3%, and established pharmaceuticals gained 2%.

Diagnostics now accounts for 36% of total revenue, up from 33% a year ago. The segment’s operating margin of 28% is also the highest among Abbott’s businesses.

Sales Across the Board: Abbott’s Diversified Business Performance in Q2 2026

U.S. sales rose 6%, while international sales grew 9%, led by strong demand in Asia-Pacific and Latin America. Currency headwinds trimmed reported revenue by roughly 1%.

Investor Sentiment Shift: Why Abbott Stock Is Attracting Bulls After the Earnings Report

Trading volume on Friday was three times the 30-day average. At least five analysts upgraded their price targets, with the median target now at $145, implying roughly 10% upside from current levels.

Previous investor concerns centered on a slowdown in Abbott’s medical device business, particularly in diabetes care. The diagnostics-driven guidance raise has largely alleviated those fears.

Abbott’s dividend yield stands at 1.8%, supported by a payout ratio of 45%. The raised guidance reinforces the company’s ability to maintain and grow its dividend.

Outlook and Risks: What Abbott’s 2026 Guidance Means for ABT Stock Holders

The diagnostics growth story faces risks. Regulatory changes to U.S. laboratory testing requirements could add compliance costs. Competition from Roche and Danaher in point-of-care platforms is intensifying.

Macroeconomic factors also matter. A stronger dollar could pressure international sales, which account for roughly 55% of total revenue. Supply chain constraints for raw materials used in test kits remain a watchpoint.

The stock now trades at 24 times forward earnings, slightly above its five-year average of 22. Some analysts argue the premium is justified given the diagnostics growth trajectory. Others caution that profit-taking could emerge after the surge.

For now, the guidance raise provides a clear floor. Abbott’s diagnostics business is generating cash and growth at a pace that few peers can match.

Data for this report was sourced from Abbott Laboratories’ Q2 2026 earnings release, Bloomberg terminal data, and analyst notes from J.P. Morgan and Goldman Sachs. The company has not provided additional commentary beyond its official filings.